The initial success of Viagra undeniably revolutionized the medication landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. Although early returns were impressive, the cessation of patents and the rise of cheaper alternatives have diminished sales. Consequently, a thorough evaluation of curr